Rezolute, Inc. will participate in the Guggenheim Biotech Summit 2026 for investor meetings on hypoglycemia treatments.
Quiver AI Summary
Rezolute, Inc. announced that its management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on February 11-12, 2026. The company, which specializes in treating hypoglycemia resulting from hyperinsulinism, will engage in one-on-one investor meetings during the event. Investors interested in meeting with the Rezolute management team can reach out to their Guggenheim representative. Rezolute is focused on its antibody therapy, ersodetug, which targets all forms of hyperinsulinism and has been evaluated in clinical trials and real-world scenarios. For more details about the company, visit their website.
Potential Positives
- Rezolute's participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 highlights its commitment to engaging with investors and increasing visibility in the biotech sector.
- The opportunity for one-on-one meetings with management demonstrates the company's focus on fostering relationships with investors, potentially leading to increased support and investment.
- The focus on a late-stage therapy, ersodetug, signals progress in Rezolute's development pipeline, which could lead to significant advancements in treatment for patients with hyperinsulinism.
Potential Negatives
- Management's participation in the conference may highlight a lack of current significant developments or announcements related to their product, ersodetug, which could suggest stagnation or uncertainty in the company's progress.
FAQ
What is Rezolute, Inc. focused on?
Rezolute, Inc. is a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI).
When is the Guggenheim Emerging Outlook: Biotech Summit 2026?
The Guggenheim Emerging Outlook: Biotech Summit 2026 will take place on February 11-12, 2026, in New York.
What therapy does Rezolute offer for hyperinsulinism?
Rezolute offers an antibody therapy called ersodetug, designed to treat all forms of hyperinsulinism (HI).
How can investors meet Rezolute's management at the summit?
Investors interested in scheduling a meeting with Rezolute's management should contact their Guggenheim representative.
Where can I find more information about Rezolute?
More information about Rezolute can be found on their official website at www.rezolutebio.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RZLT Insider Trading Activity
$RZLT insiders have traded $RZLT stock on the open market 9 times in the past 6 months. Of those trades, 9 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RZLT stock by insiders over the last 6 months:
- DARON EVANS (CFO) has made 4 purchases buying 55,549 shares for an estimated $132,744 and 0 sales.
- NEVAN C ELAM (CEO) purchased 32,000 shares for an estimated $50,880
- BRIAN KENNETH ROBERTS (Chief Medical Officer) purchased 28,000 shares for an estimated $47,600
- SUNIL RATILAL KARNAWAT (Chief Commercial Officer) has made 2 purchases buying 12,100 shares for an estimated $19,598 and 0 sales.
- WLADIMIR HOGENHUIS purchased 5,650 shares for an estimated $9,548
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RZLT Hedge Fund Activity
We have seen 79 institutional investors add shares of $RZLT stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. added 4,870,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $45,778,000
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 2,291,395 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $21,539,113
- BALYASNY ASSET MANAGEMENT L.P. added 1,822,728 shares (+inf%) to their portfolio in Q3 2025, for an estimated $17,133,643
- CALIGAN PARTNERS LP removed 1,543,014 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $14,504,331
- STATE STREET CORP added 1,261,402 shares (+152.0%) to their portfolio in Q3 2025, for an estimated $11,857,178
- BANK OF AMERICA CORP /DE/ added 1,208,408 shares (+1578.5%) to their portfolio in Q3 2025, for an estimated $11,359,035
- WOODLINE PARTNERS LP removed 965,287 shares (-50.7%) from their portfolio in Q3 2025, for an estimated $9,073,697
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RZLT Analyst Ratings
Wall Street analysts have issued reports on $RZLT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/08/2026
- Guggenheim issued a "Buy" rating on 12/12/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
To track analyst ratings and price targets for $RZLT, check out Quiver Quantitative's $RZLT forecast page.
$RZLT Price Targets
Multiple analysts have issued price targets for $RZLT recently. We have seen 6 analysts offer price targets for $RZLT in the last 6 months, with a median target of $5.5.
Here are some recent targets:
- Julian Harrison from BTIG set a target price of $5.0 on 01/08/2026
- Yun Zhong from Wedbush set a target price of $2.0 on 01/08/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $5.0 on 12/12/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $6.0 on 12/12/2025
- Jason N. Butler from Citizens set a target price of $17.0 on 10/29/2025
- Jason McCarthy from Maxim Group set a target price of $20.0 on 09/19/2025
Full Release
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York.
Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com .
Rezolute Contacts:
Christen Baglaneas
[email protected]
508-272-6717
Carrie McKim
[email protected]
336-608-9706
